Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

NCT03381066 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT03381066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03381066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.
Lead sponsor
Yonsei University
Phase
Phase 3
Overall status
Unknown status
Start date
April 10, 2018
Completion date
December 31, 2022
Enrollment
225 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

completely resected nsclc with common egfr mutations